Li Dan, Bautista Marita C, Jiang Sheng-Fang, Daryani Paras, Brackett Marilyn, Armstrong Mary Anne, Hung Yun-Yi, Postlethwaite Debbie, Ladabaum Uri
Department of Medicine and Gastroenterology, Kaiser Permanente Northern California, Santa Clara, California, USA.
Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
Am J Gastroenterol. 2016 Aug;111(8):1104-13. doi: 10.1038/ajg.2016.188. Epub 2016 May 17.
Gastric intestinal metaplasia and dysplasia are precursor lesions for adenocarcinoma. The risks of progression to malignancy from these lesions are not well characterized, particularly in the US populations.
We identified 4,331 Kaiser Permanente Northern California members who were diagnosed with gastric intestinal metaplasia or dysplasia between 1997 and 2006 and followed them through December 2013. The incident rates of gastric adenocarcinoma, relative risks in comparison with the Kaiser Permanente general population, and predictors of progression to malignancy were investigated.
Among 4,146 individuals with gastric intestinal metaplasia and 141 with low-grade dysplasia with 24,440 person-years follow-up, 17 and 6 cases of gastric adenocarcinoma were diagnosed, respectively, after 1 year from the index endoscopy. The incidence rate of gastric adenocarcinoma was 0.72/1,000 person-years in patients with intestinal metaplasia, with a relative risk of 2.56 (95% confidence interval (CI) 1.49-4.10) compared with the Kaiser Permanente member population, and 7.7/1,000 person-years for low-grade dysplasia, with a relative risk of 25.6 (95% CI, 9.4-55.7). The median time for gastric intestinal metaplasia to progress to adenocarcinoma was 6.1 years, and for low-grade dysplasia, 2.6 years. Hispanic race/ethnicity and history of dysplasia were associated with significantly higher risk of progression to gastric adenocarcinoma.
Gastric intestinal metaplasia and dysplasia are significant predictors for gastric adenocarcinoma. The low risk for malignancy associated with intestinal metaplasia does not support routine endoscopic surveillance. However, surveillance should be considered in patients at higher risks, including those with suspicious endoscopic features, presence of dysplasia, and Hispanic race/ethnicity.
胃化生和发育异常是腺癌的前驱病变。这些病变进展为恶性肿瘤的风险尚未得到充分描述,尤其是在美国人群中。
我们确定了4331名北加利福尼亚凯撒医疗集团成员,他们在1997年至2006年间被诊断为胃化生或发育异常,并对他们进行随访至2013年12月。研究了胃腺癌的发病率、与凯撒医疗集团普通人群相比的相对风险以及进展为恶性肿瘤的预测因素。
在4146例胃化生患者和141例低级别发育异常患者中,经过24440人年的随访,分别在索引内镜检查1年后诊断出17例和6例胃腺癌。胃化生患者中胃腺癌的发病率为0.72/1000人年,与凯撒医疗集团成员人群相比,相对风险为2.56(95%置信区间[CI]1.49 - 4.10);低级别发育异常患者中胃腺癌的发病率为7.7/1000人年,相对风险为25.6(95%CI,9.4 - 55.7)。胃化生进展为腺癌的中位时间为6.1年,低级别发育异常为2.6年。西班牙裔种族/族裔和发育异常病史与进展为胃腺癌的风险显著升高相关。
胃化生和发育异常是胃腺癌的重要预测因素。与胃化生相关的低恶性风险不支持进行常规内镜监测。然而,对于高危患者,包括那些具有可疑内镜特征、存在发育异常以及西班牙裔种族/族裔的患者,应考虑进行监测。